| Literature DB >> 27490037 |
Parthiban Brindha Devi1, Sridhar Jogula1, Asireddy Parameshwar Reddy1, Shalini Saxena1, Jonnalagadda Padma Sridevi1, Dharmarajan Sriram1, Perumal Yogeeswari2.
Abstract
Pantothenate synthetase (PS) enzyme involved in the pantothenate biosynthetic pathway is essential for the virulence and persistent growth of Mycobacterium tuberculosis (MTB). It is encoded by the panC gene, and has become an appropriate target for developing new therapeutics for tuberculosis. Here we report new inhibitors active against MTB PS developed using energy based pharmacophore modelling of the available proteininhibitor complex (3IVX) and virtual screening of a large commercial library. The e-pharmacophore model consisted of a ring aromatic (R), negative ionizable (N) and acceptor (A) sites. Compounds 5 and 10 emerged as promising hits with IC50 s 2.18 µM and 6.63 µM respectively. Further structural optimization was attempted to optimize lead 10 using medicinal chemistry approach and six compounds were found to exhibit better enzyme inhibition compared to parent compound lead 10 (<6 µM).Entities:
Keywords: Enzyme ïnhibition; Hit optimisation; Pantothenate synthetase; Tuberculosis; Virtual screening; e-Pharmacophore
Mesh:
Substances:
Year: 2015 PMID: 27490037 DOI: 10.1002/minf.201400120
Source DB: PubMed Journal: Mol Inform ISSN: 1868-1743 Impact factor: 3.353